NKGen Biotech

NKGen Biotech Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of NKGen Biotech (NKGN) as of Nov 22, 2026 is 47.15 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 26.46 % — a change of 78.21% (higher).

Cash Conversion

47.15 %

YoY

78.21%

Last updated:

Cash Conversion Rate (OCF/Net Income) of NKGen Biotech is 2025 47.15 % . Cash Conversion Rate (OCF/Net Income) of NKGen Biotech was 2024 26.46 % . It decreases by 78.21% higher compared to the previous year.

The NKGen Biotech Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2021
84.02 USD
Jan 1, 2022
84.31 USD
Jan 1, 2023
26.46 USD
Jan 1, 2025
47.15 USD
The NKGen Biotech Cash Conversion history
YEARCash ConversionYoY
47.15 %+78.21%
26.46 %-68.62%
84.31 %+0.34%
84.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

Cash Conversion Rate (OCF/Net Income) of NKGen Biotech is 47.15 % in 2025.

Cash Conversion Rate (OCF/Net Income) of NKGen Biotech changed from 26.46 % to 47.15 %, representing a 78.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s NKGen Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NKGen Biotech

All Key Metrics — NKGen Biotech